Literature DB >> 15023182

Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia.

J C Goldsmith1, N Eller, M Mikolajczyk, J Manischewitz, H Golding, D E Scott.   

Abstract

BACKGROUND AND OBJECTIVES: Individuals with primary or secondary immune-deficiency diseases may be at risk for vaccinia infection if widespread smallpox-immunization programmes are implemented in the United States of America (USA) for bioterrorism preparedness. The objective of this study was to determine whether commercial immune globulin (intravenous, human) products contain biologically active antibodies to vaccinia that have the potential to protect people, with immune deficiencies, from complications of vaccinia.
MATERIALS AND METHODS: Eight currently United States (US)-licensed and two European intravenous immunoglobulin (IVIG) products were tested in a vaccinia plaque-reduction neutralization assay. The in vivo activity of five of these lots was assessed in severely immune-deficient mice.
RESULTS: All tested products contained neutralizing anti-vaccinia activity, in vitro and in vivo.
CONCLUSIONS: The use of IVIG by individuals with inherited or acquired humoral immune deficiencies may provide some protection if they are inadvertently exposed to vaccinia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023182     DOI: 10.1111/j.0042-9007.2004.00397.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  7 in total

1.  Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.

Authors:  Megan M McCausland; Mohammed Rafii-El-Idrissi Benhnia; Lindsay Crickard; John Laudenslager; Steven W Granger; Tomoyuki Tahara; Ralph Kubo; Lilia Koriazova; Shinichiro Kato; Shane Crotty
Journal:  Antivir Ther       Date:  2010

Review 2.  Intravenous immunoglobulin in immunodeficiency states: state of the art.

Authors:  Elias Toubi; Amos Etzioni
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.

Authors:  Jeffry D Shearer; Linda Siemann; Mary Gerkovich; Robert V House
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice.

Authors:  Marina Zaitseva; Senta M Kapnick; John Scott; Lisa R King; Jody Manischewitz; Lev Sirota; Shantha Kodihalli; Hana Golding
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

5.  Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; Juan Moyron; John Laudenslager; Steven Granger; Sandra Rickert; Lilia Koriazova; Ralph Kubo; Shinichiro Kato; Shane Crotty
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

6.  Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.

Authors:  Lindsay Crickard; Tahar Babas; Sidharth Seth; Peter Silvera; Lilia Koriazova; Shane Crotty
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

Review 7.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.